Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Synta Pharmaceuticals Inc. (SNTA)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: SNTA
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Top Authors
Most frequent coverage on SNTA
Ohad Hammer
(176 followers)
Morphosys: A Biotech Rule Breaker (Part 2)
(Mon, Mar 30)
'When There's Blood in the Streets', Buy Biotech Stocks
(Fri, Oct 10)
Immunogen's Wild Swings Due to Lack of Information at ASCO
(Mon, Jul 14)
More by Ohad Hammer on SNTA »
Alan Brochstein
(712 followers)
Cancer Stocks Hammered Once Again
(Tue, Jun 26)
Cancer Stocks Slide Again
(Mon, Jun 18)
Cancer Stocks Plunge Following ASCO Meeting
(Mon, Jun 11)
More by Alan Brochstein on SNTA »
Mike Havrilla
(1944 followers)
1H09 Catalysts for 4 Healthcare Stocks
(Thu, Jan 8)
New Emerging Biotech and Pharma Company Index
(Sun, Nov 23)
More by Mike Havrilla on SNTA »
Most followed authors on SNTA
Mike Havrilla
(1944 followers)
1H09 Catalysts for 4 Healthcare Stocks
(Thu, Jan 8)
New Emerging Biotech and Pharma Company Index
(Sun, Nov 23)
More by Mike Havrilla on SNTA »
Alan Brochstein
(712 followers)
Cancer Stocks Hammered Once Again
(Tue, Jun 26)
Cancer Stocks Slide Again
(Mon, Jun 18)
Cancer Stocks Plunge Following ASCO Meeting
(Mon, Jun 11)
More by Alan Brochstein on SNTA »
Justin M. Hall
(672 followers)
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
(Sun, Sep 20)
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
(Fri, Sep 11)
More by Justin M. Hall on SNTA »
Newest authors on SNTA
Justin M. Hall
(672 followers)
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
(Sun, Sep 20)
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
(Fri, Sep 11)
More by Justin M. Hall on SNTA »
Mark Cifra
(30 followers)
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
(Thu, Apr 2)
More by Mark Cifra on SNTA »
Michael Becker
(165 followers)
Chink in the Biotechnology Armor
(Sun, Mar 1)
More by Michael Becker on SNTA »
Most commented on SNTA
Justin M. Hall
(672 followers)
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
(Sun, Sep 20)
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
(Fri, Sep 11)
More by Justin M. Hall on SNTA »
Ohad Hammer
(176 followers)
Morphosys: A Biotech Rule Breaker (Part 2)
(Mon, Mar 30)
'When There's Blood in the Streets', Buy Biotech Stocks
(Fri, Oct 10)
Immunogen's Wild Swings Due to Lack of Information at ASCO
(Mon, Jul 14)
More by Ohad Hammer on SNTA »
Alan Brochstein
(712 followers)
Cancer Stocks Hammered Once Again
(Tue, Jun 26)
Cancer Stocks Slide Again
(Mon, Jun 18)
Cancer Stocks Plunge Following ASCO Meeting
(Mon, Jun 11)
More by Alan Brochstein on SNTA »